Tech Company Financing Transactions
Attune Pharmaceuticals Funding Round
Venrock, Boxer Capital and LifeSci Venture Partners participated in a $23 million Series B capital raise for Attune Pharmaceuticals. The round was recorded on 1/24/2019.
Transaction Overview
Company Name
Announced On
1/24/2019
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Series B
Investors
Venrock (Lead Investor) (Bong Koh)
Proceeds Purpose
Proceeds of the Series B round will be used to advance Attune's pipeline, which includes the ongoing clinical development of ATN-249, a novel orally-administered plasma kallikrein inhibitor for the treatment of Hereditary Angioedema (HAE).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
250 West 55th St. 34th Floor
New York, NY 10019
USA
New York, NY 10019
USA
Phone
Website
Email Address
Overview
Attune Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of novel once-daily small molecule therapeutics for treatment of rare diseases. Attune Pharmaceuticals is currently advancing two programs, one in Hereditary Angioedema (HAE) and a second in complement-mediated diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Andrew McDonald
Chief Marketing Officer
Ira Kalfus
Chief Operating Officer
Jason Bablak
Browse more venture capital transactions:
Prev: 1/24/2019: Confluent venture capital transaction
Next: 1/24/2019: Urgent.ly venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs